何伟福开题报告幻灯片精品.pptVIP

五、主要参考文献 [1] Wilhelm SM, Carter C, Tang L, et al. BAY43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004；64（19）：7099－7109. [2] Strumberg D, Richly H, Hilger RA, et al. Phase Ⅰ chlinical and pharmacok inetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY43－9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005；23（5）：965 [3] Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 2005;23:6771–6790. [4] Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965–972. [5] Hotte SJ, Hirte HW. BAY 43-9006: early clinical data in patients with advanced solid malignancies. Curr Pharm Des 2002;8:2249–2253. [6] 周爱萍，孙 燕. 多靶点抗肿瘤新药索拉非尼的研究进展.文献综述. 癌症进展杂志. 2006；4（6）：529－533 [7] Ratain MJ, Eisen T, Stadler WM, et al. Final findings from a phaseⅡ，placebo-controlled，randomized discontinuation trial（RDT）of Sorafenib（Bay43－9006）in patients with advanced renal cell carcinoma（RCC）Abstract. J Clin Oncol. 2005;23：4544. [8] Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004;10:6388S–92S. [9] Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of Bay 43-006 in patients with advanced hepatocellular carcinoma (HCC). In: Proceedings of the 2004 AACR-NCI-WORTC International Conference on Molecular Targets and Cancer Therapeutics; 2004. 山西医科大学研究生学位论文开题报告 山西医科大学研究生学位论文开题报告 导 师：刘建生教授 研究生：何伟福 索拉非尼抑制胰腺癌PC-3细胞增殖的实验研究 立论依据 研究方案 研究基础 经费预算 参考文献 一、立论依据 胰腺癌是恶性程度极高的常见消化系肿瘤,已成为世界第4或第5大癌症